Hendifar A - Search Results

1

Advances in Pancreatic Ductal Adenocarcinoma Treatment.

Anderson EM, Thomassian S, Gong J, Hendifar A, Osipov A. Anderson EM, et al. Among authors: hendifar a. Cancers (Basel). 2021 Nov 3;13(21):5510. doi: 10.3390/cancers13215510. Cancers (Basel). 2021. PMID: 34771675 Free PMC article. Review.

2

Review of systemic therapies for locally advanced and metastatic rectal cancer.

Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Yaffee P, et al. Among authors: hendifar a. J Gastrointest Oncol. 2015 Apr;6(2):185-200. doi: 10.3978/j.issn.2078-6891.2014.112. J Gastrointest Oncol. 2015. PMID: 25830038 Free PMC article. Review.

3

Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma.

Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R. Hendifar A, et al. PLoS One. 2016 Mar 25;11(3):e0152172. doi: 10.1371/journal.pone.0152172. eCollection 2016. PLoS One. 2016. PMID: 27015568 Free PMC article.

4

Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy.

Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M, Annamalai A, Nissen NN, Tuli R. Osipov A, et al. Among authors: hendifar a. J Gastrointest Oncol. 2016 Apr;7(2):239-47. doi: 10.3978/j.issn.2078-6891.2015.109. J Gastrointest Oncol. 2016. PMID: 27034792 Free PMC article.

5

Targeting mTOR in Pancreatic Ductal Adenocarcinoma.

Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE. Iriana S, et al. Front Oncol. 2016 Apr 25;6:99. doi: 10.3389/fonc.2016.00099. eCollection 2016. Front Oncol. 2016. PMID: 27200288 Free PMC article. Review.

6

Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients.

Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Yue Y, et al. Among authors: hendifar a. J Gastrointest Oncol. 2017 Feb;8(1):127-138. doi: 10.21037/jgo.2016.12.04. J Gastrointest Oncol. 2017. PMID: 28280617 Free PMC article.

7

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.

Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. Singhi AD, et al. Among authors: hendifar a. J Natl Compr Canc Netw. 2017 May;15(5):555-562. doi: 10.6004/jnccn.2017.0058. J Natl Compr Canc Netw. 2017. PMID: 28476735

8

Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.

Osipov A, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R. Osipov A, et al. Among authors: hendifar ae. Ann Surg Oncol. 2017 Nov;24(12):3674-3682. doi: 10.1245/s10434-017-6076-z. Epub 2017 Sep 5. Ann Surg Oncol. 2017. PMID: 28871564

9

Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point.

Gong J, Wu D, Chuang J, Tuli R, Simard J, Hendifar A. Gong J, et al. Among authors: hendifar a. Clin Ther. 2017 Nov;39(11):2135-2145. doi: 10.1016/j.clinthera.2017.09.015. Epub 2017 Oct 25. Clin Ther. 2017. PMID: 29079389 Review.

10

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.

Gong J, Yan J, Forscher C, Hendifar A. Gong J, et al. Among authors: hendifar a. Drug Des Devel Ther. 2018 Apr 6;12:777-786. doi: 10.2147/DDDT.S140638. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29670334 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

170 results

Search Page